Table 1.
Treatment | VMN | POA | CTX |
---|---|---|---|
V | 1.0 | 1.0 | 1.0 |
EB | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 |
P | 1.0 ± 0.1 | 1.1 ± 0.1 | 1.3 ± 0.2 |
EB+P | 1.0 ± 0.3 | 1.0 ± 0.2 | 1.2 ± 0.2 |
Analysis of the Western blots from the extracts used in the kinase assays are shown. The intensities of the total CaMKIIα (50-kDa band only) and the GAPDH (37 kDa) bands in each of the treatment groups were quantified using a densitometer. The ratio of CaMKIIα and -β to GAPDH in each lane was calculated. Because the values were similar, only the values for the 50-kDa subunit are presented. This ratio for the vehicle (V) was equated to 1 and compared with those of the steroid treatments. Column 1 indicates the various treatments (V, EB, P, and EB+P). Columns 2, 3, and 4 represent the average (n = 6) values of total CaMKII in the VMN, POA, and CTX for each treatment group. ANOVA showed no significant differences in the mean values (P < 0.05) for VMN, POA, and CTX samples. Dunnett’s post hoc multiple comparisons showed no significant differences between the groups in each region of the brain (P > 0.05; n = 6).